Cholestanol: A serum marker to guide LDL cholesterol-lowering therapy

被引：16

作者：

Hoenig, MR ^{[1
]}

Rolfe, BE ^{[1
]}

Campbell, JH ^{[1
]}

机构：

[1] Royal Brisbane & Womens Hosp, Brisbane, Qld 4029, Australia

来源：

ATHEROSCLEROSIS | 2006年 / 184卷 / 02期

关键词：

LDL; cholestanol; cholesterol; statins; ezetimibe; bile acid binding resins; NCEP ATPIII;

D O I：

10.1016/j.atherosclerosis.2005.09.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Statins have been the mainstay of lipid-lowering therapy since their introduction. However, as lower LDL cholesterol targets are sought, adjunct therapies are becoming increasingly important. Few patients reach new targets with statin monotherapy. We propose that the cholestanol: cholesterol ratio can be used to guide lipid-lowering therapy and result in greater numbers of patients reaching target LDL cholesterol. By determining whether a patient is mainly a synthesizer or absorber of cholesterol, customized regimens can be used and are expected to improve patient outcomes and minimize costs of treatment. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

引用

页码：247 / 254

页数：8

共 86 条

[1] Statin compliance in the Umbrian population [J].

Abraha, I ;

Montedori, A ;

Stracci, F ;

Rossi, M ;

Romagnoli, C .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) :659-661

[2] The safety of rosuvastatin as used in common clinical practice - A postmarketing analysis [J].

Alsheikh-Ali, AA ;

Ambrose, MS ;

Kuvin, JT ;

Karas, RH .

CIRCULATION, 2005, 111 (23) :3051-3057

[3] Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption [J].

Altmann, SW ;

Davis, HR ;

Zhu, LJ ;

Yao, XR ;

Hoos, LM ;

Tetzloff, G ;

Iyer, SPN ;

Maguire, M ;

Golovko, A ;

Zeng, M ;

Wang, LQ ;

Murgolo, N ;

Graziano, MP .

SCIENCE, 2004, 303 (5661) :1201-1204

[4] Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins [J].

Andrews, TC ;

Ballantyne, CM ;

Hsia, JA ;

Kramer, JH .

AMERICAN JOURNAL OF MEDICINE, 2001, 111 (03) :185-191

[5] Prevention and Rehabilitation - Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study [J].

Ballantyne, CM ;

Abate, N ;

Yuan, Z ;

King, TR ;

Palmisano, J .

AMERICAN HEART JOURNAL, 2005, 149 (03) :464-473

[6] Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy [J].

Ballantyne, CM ;

Herd, JA ;

Ferlic, LL ;

Dunn, JK ;

Farmer, JA ;

Jones, PH ;

Schein, JR ;

Gotto, AM .

CIRCULATION, 1999, 99 (06) :736-743

[7] Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters [J].

Berge, KE ;

Tian, H ;

Graf, GA ;

Yu, LQ ;

Grishin, NV ;

Schultz, J ;

Kwiterovich, P ;

Shan, B ;

Barnes, R ;

Hobbs, HH .

SCIENCE, 2000, 290 (5497) :1771-1775

[8] Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors -: The role of metabolism -: Monograph for physicians [J].

Bottorff, M .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2273-2280

[9] Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia [J].

Bruckert, E ;

Simonetta, C ;

Giral, P .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (06) :589-594

[10] BETA-HYDROXY-BETA-METHYLGLUTARYL COENZYME A REDUCTASE, CLEAVAGE AND CONDENSING ENZYMES IN RELATION TO CHOLESTEROL FORMATION IN RAT LIVER [J].

BUCHER, NLR ;

OVERATH, P ;

LYNEN, F .

BIOCHIMICA ET BIOPHYSICA ACTA, 1960, 40 (03) :491-501

← 1 2 3 4 5 6 7 8 9 →